Biological Basis for the Co-morbidity Between Smoking and Mood Disorders

Abstract

Nicotine dependence is still the major preventable cause of death in the developed world, and it has strong co-morbidity with mood disorders including major depression. Depressed patients are more likely to smoke cigarettes, and quitting can precipitate an episode of depression in some individuals. Interestingly, antidepressants, particularly the atypical antidepressant bupropion, are therapeutics that can help smokers quit. Despite these observations, the underlying biological factors of the relationship between smoking and depression remain unclear. Results from clinical and preclinical studies have seemed somewhat paradoxical because heightened cholinergic activity can induce depression, while both nicotine and nicotinic antagonists can be antidepressant-like. These observations can be reconciled by considering that high-affinity nicotinic receptors in the brain can be desensitized by chronic nicotine use, leading to blunted cholinergic activity. Based on this hypothesis, nicotinic antagonists have recently been tested as treatments for depression in humans, particularly as adjunct therapy along with classical antidepressants. These data suggest that the relationship between smoking and depression may be partially explained by the fact that depressed patients smoke in an effort to self-medicate depressive symptoms by desensitizing their nicotinic receptors. This possibility suggests new avenues for treatment of both nicotine dependence and depressive disorders.

KEYWORDS:

• Translational science
• mouse models
• human studies
• review
• depression
• major depressive disorder
• knockout mice
• nicotine
• nicotinic acetylcholine receptors

This work was supported by the State of Connecticut, Department of Mental Health and Addiction Services and National Institutes of Health grants MH77681 and DA00436.